Researchers are exploring a novel approach to treating Alzheimer’s disease, adapting a strategy previously successful in cancer therapy to target the neurodegenerative condition. This research offers a potential new avenue for tackling a disease that currently has limited treatment options, impacting millions worldwide.
Like recently approved Alzheimer’s treatments from companies like Eli Lilly, this new therapy aims to activate the brain’s immune system to clear amyloid plaques – deposits of the protein A-beta that accumulate in the brain and are believed to contribute to the disease’s progression. Existing treatments, such as aducanumab and crenezumab, work by activating microglia, immune cells in the brain, to attack these plaques and slow the disease’s advancement. However, these therapies often require repeated antibody injections and high doses to achieve effective concentrations in the brain.
The new approach, developed by Chen, Liu, Nguyen, and colleagues, involves engineering cells derived from an animal model of Alzheimer’s disease. These cells are modified to display a portion of a previously used antibody on their surface, alongside other proteins that activate cellular programs. This activation triggers the microglia or astrocytes – brain cells similar to T cells in the rest of the body – to become active. The modified cells are then returned to the animal to observe which system is most effective at targeting amyloid plaques.
The study, while preliminary, represents a potentially significant shift in Alzheimer’s treatment paradigms. Researchers demonstrated the possibility of developing personalized therapies tailored to individual patients. If a sufficiently effective procedure can be developed, this therapy could be particularly suitable for those in the early stages of the disease or with significant risk factors, including those with familial forms of Alzheimer’s. Interestingly, the two types of CAR-A tested appear to act through slightly different pathways, with one primarily targeting astrocytes and the other activating both microglia and astrocytes in the partial but significant removal of amyloid plaques.
The research team found that the engineered cells continued to divide and form new cells for at least three months after administration, suggesting a potentially sustained effect from a single treatment. However, they did not observe any improvement in the animals’ cognitive abilities at five or nine months post-treatment. This highlights the complexity of Alzheimer’s disease and the challenges of translating plaque reduction into functional benefits.
The study likewise noted some potential side effects, which, while not severe in the animal models, warrant further investigation before potential human trials. This is a crucial step in ensuring patient safety.
In a simplified view, this new therapy could represent an improved version of current monoclonal antibody treatments, should it successfully navigate the initial phases of development. As [Cognition Therapeutics, Inc.](https://news.google.com/rss/articles/CBMi9AFBVV95cUxPdDA4TS1Nd1VjMlpPdzc2djBkWXd1djNCREh2UEFfa0Mtd3pwMmJvbk1kNkhJWVQ3RHVCYUZBVU1jdXpMZUlPRWZfQl9QUUJlQ2lqRVM2NjZzTk1BVEk3YnNseGZLUGtHSUx0RDN0a0pzcEY5c243eFhUcU9RZmZpWS1hcjNyN01uOUxQazdRTzhteVdfbXRFOWRUR2hwYlVRbGZRVmhUQmw3Wk5ISU8zUGZpNGhCUmZUMkxxWDdaMk42MVVhLTlGN1Y5eUNzaE1pdU03dWZzY3VjT29oRUVTaGFXRXJFd3dwdFhudnpwemxRbW5V?oc=5) plans to align with the EMA on Alzheimer’s disease strategy for zervimesine, the regulatory landscape is also evolving.
A key limitation of the study is its reliance on a transgenic mouse model, which may not fully replicate the complexities of human Alzheimer’s disease. The lack of observed functional improvement also tempers expectations in the short term. Reducing amyloid plaque burden is a relative success if it doesn’t translate into improved cognitive function. Researchers suggest they may be at a stage of development where such improvements are not yet detectable.
Further research is needed to determine which patients might benefit most from this potential therapy and to identify the optimal method of delivery for the adenovirus vectors used in the process. These are important considerations as the research progresses toward potential clinical applications.
This work presents several promising aspects, including its potential effectiveness in cases of genetic risk, the activation of both microglia and astrocytes, and the possibility of a single-dose treatment. However, it remains uncertain whether these promises will be fulfilled. Similar experimental approaches have shown varying degrees of success, but collectively offer a degree of optimism regarding the possibility of developing an effective therapy for plaque removal. As [European regulators](https://news.google.com/rss/articles/CBMijwFBVV95cUxQd000anA2bHJidl8yQnYtT0VzOXNTaHBNRmJiQ1pfNFhNN1NtR1NqMlZLWUY3MUZVbVFlSXc4MWhvYkhYQnhQSVlqcDB0dHZSYWJoWGMzTmVIR004RW9YQzRKemlnRlJPNFVxWmltNVkySnBHM2EtVV9Lb2txX0RsUHVuc1Iwd1dEaG1wcVlBaw?oc=5) endorse Lilly’s Alzheimer’s treatment for certain patients, the field continues to advance.
The question of when this therapy might become available to patients, and whether it will be effective in advanced stages of the disease, remains unanswered. Given the preliminary nature of the research, widespread clinical application is not expected in the near future. [Eli Lilly’s Kisunla](https://news.google.com/rss/articles/CBMivgFBVV95cUxQNk1ubmI5S2Zhbmg5LTg4ajZnMUg0ZE95UnA3djBxNTFCOXUwSHkyOHNJazJ6VjRJaS1iMU8teEpCUHpKdVJSZlFpczl6dllCNDVrWXBnS05YeWU3MGF1cHlGQklPa05XWWJxU0YwaEwtcjZhVFRFVFg1TUQ4Q2ZTd09xWkZWMXkyb0h2YjJQWnR0MFZwUi02VXlibTdYRTJGUkU5UmtBbW80OGJCcU5XODZ2blhQbzlDNm9YcktB?oc=5) recently won FDA nod for new dosing with fewer side effects, demonstrating ongoing innovation in Alzheimer’s treatment.
